Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture/St. Jude Children's Research Hospital

Drug Profile

Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture/St. Jude Children's Research Hospital

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Eisai Co Ltd; Medicines for Malaria Venture; St. Jude Childrens Research Hospital
  • Class Isoquinolines; Small molecules
  • Mechanism of Action Calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Malaria

Most Recent Events

  • 15 Feb 2016 Eisai Co Ltd and Charles River Laboratories collaborate to develop Malaria therapeutics
  • 04 Nov 2015 Eisai, Liverpool School of Tropical Medicine, University of Liverpool receive a grant from Global Health Innovative Technology Fund for drug development in Malaria
  • 16 Sep 2014 Eisai, St. Jude Children's Research Hospital and Medicines for Malaria Venture receive a grant from Global health Innovative Technology Fund for drug development in Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top